MX2014005249A - N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]s ulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-cinasa para el tratamiento de neoplasias malignas linfoproliferativas. - Google Patents

N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]s ulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-cinasa para el tratamiento de neoplasias malignas linfoproliferativas.

Info

Publication number
MX2014005249A
MX2014005249A MX2014005249A MX2014005249A MX2014005249A MX 2014005249 A MX2014005249 A MX 2014005249A MX 2014005249 A MX2014005249 A MX 2014005249A MX 2014005249 A MX2014005249 A MX 2014005249A MX 2014005249 A MX2014005249 A MX 2014005249A
Authority
MX
Mexico
Prior art keywords
amino
treatment
methylalaninamide
quinoxalin
phosphatidylinositol
Prior art date
Application number
MX2014005249A
Other languages
English (en)
Inventor
Arthur Decillis
Joanne Lager
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014005249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2014005249A publication Critical patent/MX2014005249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para el tratamiento de una neoplastia linfoproliferativa a un paciente en necesidad del tratamiento, comprendiendo la administración al paciente de una cantidad efectiva del compuesto A como se describe aquí.
MX2014005249A 2011-11-01 2012-11-01 N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]s ulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-cinasa para el tratamiento de neoplasias malignas linfoproliferativas. MX2014005249A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553990P 2011-11-01 2011-11-01
US201161568189P 2011-12-08 2011-12-08
PCT/US2012/062999 WO2013067141A1 (en) 2011-11-01 2012-11-01 N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies

Publications (1)

Publication Number Publication Date
MX2014005249A true MX2014005249A (es) 2015-03-05

Family

ID=47295148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005249A MX2014005249A (es) 2011-11-01 2012-11-01 N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]s ulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-cinasa para el tratamiento de neoplasias malignas linfoproliferativas.

Country Status (21)

Country Link
US (2) US20140303172A1 (es)
EP (1) EP2773353B1 (es)
JP (1) JP6013498B2 (es)
KR (1) KR20140096083A (es)
CN (2) CN104302294A (es)
AU (2) AU2012332486A1 (es)
BR (1) BR112014010492A2 (es)
CA (1) CA2854159A1 (es)
CL (1) CL2014001138A1 (es)
CR (1) CR20140253A (es)
DO (1) DOP2014000092A (es)
EA (1) EA201490905A1 (es)
EC (1) ECSP14002014A (es)
HK (1) HK1201480A1 (es)
IL (1) IL232398A0 (es)
MX (1) MX2014005249A (es)
NI (1) NI201400037A (es)
PE (1) PE20141794A1 (es)
SG (1) SG11201401961UA (es)
WO (1) WO2013067141A1 (es)
ZA (1) ZA201403258B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
AR092501A1 (es) * 2012-09-13 2015-04-22 Sanofi Sa Compuestos cristalinos
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP5270353B2 (ja) * 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CN101395155A (zh) 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2139484B9 (en) 2007-04-10 2014-06-11 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
US8481001B2 (en) * 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
US20100150827A1 (en) 2007-04-11 2010-06-17 Exelixis, Inc Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
CN101711249A (zh) 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2712267A1 (en) * 2008-01-15 2009-07-23 Wyeth Llc 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
WO2010120998A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
KR20120034666A (ko) 2009-05-22 2012-04-12 엑셀리시스, 인코포레이티드 증식성 질환에 대한 벤족사제핀 기반 ｐ１３ｋ／ｍｔ０ｒ의 억제제
CA2763008A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AU2011274510A1 (en) * 2010-07-09 2013-01-24 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TWI617560B (zh) 2010-09-14 2018-03-11 伊塞利克斯公司 PI3Kδ 抑制劑以及其應用和生產方法
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012071519A1 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
US20140073628A1 (en) 2010-11-24 2014-03-13 Kenneth D. Rice Benzoxazepines asn inhibitors of p13k/m tor and methods of their use and manufacture
JP2013544827A (ja) 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法
US20140378436A9 (en) 2010-11-24 2014-12-25 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
BR112013012961A2 (pt) 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
TW201311683A (zh) 2011-04-29 2013-03-16 Exelixis Inc 使用吡啶并嘧啶酮ｐｉ３ｋ／ｍｔｏｒ抑制劑治療淋巴瘤之方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators

Also Published As

Publication number Publication date
EA201490905A1 (ru) 2014-11-28
AU2012332486A1 (en) 2014-06-19
AU2017219131A1 (en) 2017-09-28
CL2014001138A1 (es) 2014-08-01
HK1201480A1 (en) 2015-09-04
US20140303172A1 (en) 2014-10-09
JP2014532709A (ja) 2014-12-08
IL232398A0 (en) 2014-06-30
JP6013498B2 (ja) 2016-10-25
DOP2014000092A (es) 2015-02-15
CN107375289A (zh) 2017-11-24
KR20140096083A (ko) 2014-08-04
ECSP14002014A (es) 2015-11-30
EP2773353B1 (en) 2018-09-05
EP2773353A1 (en) 2014-09-10
US20170296529A1 (en) 2017-10-19
US10328069B2 (en) 2019-06-25
ZA201403258B (en) 2015-11-25
CN104302294A (zh) 2015-01-21
BR112014010492A2 (pt) 2017-04-25
PE20141794A1 (es) 2014-12-17
WO2013067141A1 (en) 2013-05-10
CR20140253A (es) 2014-10-28
SG11201401961UA (en) 2014-05-29
CA2854159A1 (en) 2013-05-10
NI201400037A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
UA116765C2 (uk) (гетеро)арилциклопропіламіни як інгібітори lsd1
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
NZ615270A (en) Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer
MX2014004429A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
UA111382C2 (uk) Інгібітори протеїнкінази
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX341732B (es) Inhibidores de la demetilasa lsd1 basados en arilciclopropilamina y sus usos médicos.
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
PH12015501038A1 (en) Inhibitors of iap
GB201209587D0 (en) Therapeutic compounds
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX2014005249A (es) N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]s ulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-cinasa para el tratamiento de neoplasias malignas linfoproliferativas.
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
TN2014000184A1 (en) N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1
UA59343U (ru) Применение теобона-дитиомикоцида (n -(1,1-диоксотиолан-3-ил)-дитиокарбамата калия) как средства для лечения инфекционных поражений кожи